文献速递胸部肿瘤

再挑战获益评分:免疫治疗后进展患者的临床决策工具

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.
PubMed 文献 · Eur J Cancer · 2025-11-15

研究基于80例在16个法国中心接受ICI再挑战的NSCLC患者,利用前两个ICI周期前的17项常规血液检测构建机器学习评分RBS。低RBS组中位rPFS显著长于高RBS组(6.4 vs 1.9个月,p<0.0001,HR=0.31,95%CI 0.17-0.55),且RBS对化疗或一线ICI队列无预测价值。

要点

  • RBS可识别ICI再挑战后rPFS更长的患者,C-index为0.79。
  • 低RBS组中位rPFS为6.4个月,高RBS组为1.9个月。
  • 仅凭临床特征不足以可靠识别ICI再挑战获益人群。

核心结论

  • RBS评分可筛选可能从ICI再挑战中获益的NSCLC患者,弥补临床特征不足。

研究设计与样本

  • 多中心回顾性研究,分析80例在16个法国中心接受ICI再挑战的NSCLC患者前两个周期前的17项常规血液检测。
  • 采用稳健机器学习方法识别与再挑战无进展生存期(rPFS)相关的生物学参数并构建整合评分。
  • 在化疗队列(n=82)和一线ICI队列(n=252)中评估RBS的预测特异性。

主要发现

  • RBS识别ICI再挑战临床获益更长的患者,C-index为0.79,不受临床特征影响。
  • 低RBS组中位rPFS为6.4个月,高RBS组为1.9个月,差异显著(p<0.0001,HR=0.31,95%CI 0.17-0.55)。
  • RBS对化疗队列和一线ICI队列的获益无预测价值,具有特异性。

关键数值与推荐

  • RBS基于前两个ICI周期前的17项常规血液检测构建。
  • 低RBS组中位rPFS 6.4个月,高RBS组1.9个月(p<0.0001,HR=0.31,95%CI 0.17-0.55)。
  • RBS预测ICI再挑战获益的C-index为0.79。

临床怎么用

  • 对既往ICI治疗后进展的NSCLC患者,可考虑用RBS辅助筛选ICI再挑战候选者。
  • RBS不适用于预测化疗或一线ICI的获益,应仅用于再挑战决策场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with advanced Non-Small-Cell Lung Cancer (NSCLC) receive an immune checkpoint inhibitor (ICI) as first-line treatment. Upon progression, therapeutic options are limited, making ICI rechallenge a relevant strategy. However, identifying patients who may benefit remains challenging. This study presents a predictive score to guide treatment decisions. METHODS: Seventeen routine blood tests performed before the first two ICI cycles were analyzed in 80 NSCLC patients rechallenged across 16 French centers. Using a robust machine learning approach, we identified biological parameters associated with progression-free survival during rechallenge (rPFS) and developed an integrative score able to stratify patients according to rPFS. Its predictive value was assessed in relation to patients treated with chemotherapy after ICI (n = 82) and to their outcomes evaluated during first-line immunotherapy (n = 252). RESULTS: Our findings indicate that clinical characteristics alone are insufficient to reliably identify patients who are likely to respond to ICI rechallenge. We identify the Rechallenge Benefit Score (RBS), which identifies patients likely to achieve longer clinical benefit from ICI rechallenge (C-index 0.79), regardless of clinical characteristics. Median rPFS was significantly longer in patients with low versus high RBS (6.4 and 1.9 months respectively; p < 0.0001, HR=0.31, 95 % CI:0.17-0.55). Notably, the RBS is specific, as it does not predict benefit in Chemotherapy or first-line ICI cohorts. CONCLUSION: We identified and validated the RBS score to select patients likely to benefit from ICI rechallenge. Since clinical features alone are insufficient, our findings may guide treatment strategies for patients who experienced disease progression during prior ICI treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Plazy C, Boussena M, Nguyen Phuong L, et al. The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy. Eur J Cancer. 2025. PMID: 41275528. doi:10.1016/j.ejca.2025.116115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。